BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar
Patrick J Tang,
Mohammad Rubayet Hasan,
HADI M. YASSINE,
Hebah A. Al Khatib,
Houssein H. Ayoub,
Einas Al Kuwari,
Anvar Hassan Kaleeckal,
Ali Nizar Latif,
Riyazuddin Mohammad Shaik,
Hanan F. Abdul Rahim,
Mohamed Ghaith Al Kuwari,
Hamad Eid Al Romaihi,
Adeel A Butt,
Mohamed H. Al-Thani,
Abdullatif Al Khal,
Laith J Abu-Raddad
Posted 11 Aug 2021
medRxiv DOI: 10.1101/2021.08.11.21261885
Posted 11 Aug 2021
The SARS-CoV-2 Delta (B.1.617.2) variant of concern is expanding globally. Here, we assess real-world effectiveness of the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines against this variant in the population of Qatar, using a matched test-negative, case-control study design. BNT162b2 effectiveness against any Delta infection, symptomatic or asymptomatic, was 64.2% (95% CI: 38.1-80.1%) [≥]14 days after the first dose and before the second dose, but was only 53.5% (95% CI: 43.9-61.4%) [≥]14 days after the second dose, in a population in which a large proportion of fully vaccinated persons received their second dose several months earlier. Corresponding effectiveness measures for mRNA-1273 were 79.0% (95% CI: 58.9-90.1%) and 84.8% (95% CI: 75.9-90.8%), respectively. Effectiveness against any severe, critical, or fatal COVID-19 disease due to Delta was 89.7% (95% CI: 61.0-98.1%) for BNT162b2 and 100.0% (95% CI: 41.2-100.0%) for mRNA-1273, [≥]14 days after the second dose. Both BNT162b2 and mRNA-1273 are highly effective in preventing Delta hospitalization and death, but less so in preventing infection, particularly for BNT162b2.
- Downloaded 13,283 times
- Download rankings, all-time:
- Site-wide: 746
- In epidemiology: 106
- Year to date:
- Site-wide: 215
- Since beginning of last month:
- Site-wide: 312
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!